Point72 Asset Management
VRDN icon

Point72 Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Point72 Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43M Buy
2,343,208
+2,020,372
+626% +$32.6M 0.05% 493
2026
Q1 		$6.31M Buy
322,836
+68,551
+27% +$2.04M 0.01% 1543
2025
Q4 		$7.91M Buy
+254,285
New +$6.97M 0.01% 1500
2025
Q3 		– Sell
-104,043
Closed -$1.45M – 2712
2025
Q2 		$1.45M Sell
104,043
-100,659
-49% -$1.37M ﹤0.01% 1428
2025
Q1 		$2.76M Buy
+204,702
New +$3.49M 0.01% 1141
2024
Q4 		– Sell
-34,627
Closed -$788K – 2488
2024
Q3 		$788K Buy
+34,627
New +$566K ﹤0.01% 1496
2023
Q4 		– Sell
-439,191
Closed -$6.74M – 2881
2023
Q3 		$6.74M Buy
+439,191
New +$8.38M 0.02% 790
2023
Q2 		– Sell
-57,100
Closed -$1.45M – 2826
2023
Q1 		$1.45M Sell
57,100
-202,991
-78% -$6.51M ﹤0.01% 1041
2022
Q4 		$7.6M Sell
260,091
-26,616
-9% -$613K 0.03% 635
2022
Q3 		$5.88M Sell
286,707
-503,693
-64% -$9.05M 0.02% 666
2022
Q2 		$9.14M Buy
790,400
+490,400
+163% +$6.59M 0.04% 529
2022
Q1 		$5.55M Sell
300,000
-172,864
-37% -$3.32M 0.02% 675
2021
Q4 		$9.35M Sell
472,864
-137,136
-22% -$2.55M 0.04% 528
2021
Q3 		$10M Buy
610,000
+214,466
+54% +$3.15M 0.04% 488
2021
Q2 		$7.23M Hold
395,534
– – 0.03% 525
2021
Q1 		$6.61M Sell
395,534
-30,628
-7% -$573K 0.03% 523
2020
Q4 		$7.01M Buy
+426,162
New +$6.42M 0.03% 524
2020
Q1 		– Sell
-6,646
Closed -$48K – 1104
2019
Q4 		$48K Hold
6,646
– – ﹤0.01% 896
2019
Q3 		$73K Hold
6,646
– – ﹤0.01% 1020
2019
Q2 		$204K Sell
6,646
-1,000
-13% -$40.1K ﹤0.01% 964
2019
Q1 		$320K Hold
7,646
– – ﹤0.01% 905
2018
Q4 		$348K Sell
7,646
-16,354
-68% -$946K ﹤0.01% 886
2018
Q3 		$2.01M Buy
+24,000
New +$2.26M 0.01% 759

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management's VRDN Position: Q2 2026 in Review

Point72 Asset Management increased its Viridian Therapeutics (VRDN) stake by 626% in Q2 2026, buying an estimated $32.6M and bringing the position to 2,343,208 shares worth $43M. The position accounts for 0.05% of the portfolio, ranked #493.

Point72 Asset Management first reported a position in VRDN in Q3 2018 and has held it in 23 quarters since. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Point72 Asset Management held 2,343,208 shares of Viridian Therapeutics worth $43M as of Q2 2026.
  • Point72 Asset Management bought 2,020,372 Viridian Therapeutics shares in Q2 2026, an estimated $32.6M.
  • Viridian Therapeutics made up 0.05% of Point72 Asset Management's portfolio in Q2 2026, its #493 holding.
  • Point72 Asset Management first reported a position in Viridian Therapeutics in Q3 2018 and has held it in 23 quarters since.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.